Physician profile
Sumit Bhutani
NPI 1306872619
$10,719.05
in general payments reported to CMS, 2019-2025
32 companies · $3,052 in 2025
The $3,052 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $917 · 2021: $1,775 · 2022: $1,784 · 2023: $693 · 2024: $1,917 · 2025: $3,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875 · Consulting Fee: $2,766 · Education: $17.71 · Travel and Lodging: $2.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.22 |
| Consulting Fee | $2,766.00 |
| Education | $17.71 |
| Travel and Lodging | $2.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,910.38 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,355.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $825.97 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $343.12 | 2019-2024 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $269.61 | 2025 | Neffy |
| Grifols USA, LLC | $256.05 | 2019-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $250.92 | 2023-2025 | |
| Octapharma USA, INC. | $176.59 | 2020-2021 | |
| Leo Pharma INC. | $161.21 | 2022-2025 | Adbry, Anzupgo |
| Optinose US, INC. | $118.90 | 2021-2025 | |
| Organon LLC | $113.15 | 2025 | Vtama |
| Takeda Pharmaceuticals U.S.A., INC. | $105.79 | 2021-2025 | Takhzyro, Gattex |
| Teva Pharmaceuticals USA, INC. | $105.09 | 2020-2021 | |
| Ionis Pharmaceuticals, INC. | $98.58 | 2025 | Dawnzera |
| Genentech USA, INC. | $74.07 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $61.79 | 2025 | Haegarda, Andembry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.43 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Pfizer INC. | $49.47 | 2019-2023 | |
| Alk-Abello, INC | $45.44 | 2019 | |
| Incyte Corporation | $42.92 | 2024-2025 | Opzelura |
| Galderma Laboratories, L.P. | $37.84 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $32.70 | 2025 | Sajazir |
| Pharming Healthcare, INC. | $29.03 | 2025 | Ruconest |
| Amgen INC. | $26.36 | 2022 | |
| Aimmune Therapeutics, INC. | $24.72 | 2025 | Vowst |
| Hospira, INC. | $24.69 | 2025 | |
| Olympus America INC. | $22.85 | 2024 | Olympus |
| Abbvie INC. | $21.81 | 2023 | Rinvoq |
| Sanofi-Aventis U.S. LLC | $19.88 | 2020 | |
| Kaleo, INC. | $19.29 | 2019 | |
| Uswm, LLC | $17.64 | 2021 | |
| Phadia US INC. | $17.24 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Bhutani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.